Mentice publishes the company’s interim report for the period July – September 2024

SIGNIFICANT EVENTS DURING THE THIRD QUARTER 2024 (JUL – SEP)

• Mentice and AGIK, the Working Group of Interventional Cardiology within the German Society of Cardiology (DGK), have announced a strategic three-year partnership to transform interventional cardiology training in Germany.

SIGNIFICANT EVENTS AFTER END OF PERIOD

• Mentice announced a significant order from a top 20 global Med Tech company, a long-standing customer of Mentice, of 630 000 USD
• Mentice announced a significant order from a top 20 global Med Tech company of 1 062 750 EURO.
• Mentice launched the VIST Ankyras integration, allowing for physicians to rehearse a procedure based on the results of an Ankyras simulation.

THIRD QUARTER 2024 (JUL- SEP)

• Order intake amounted to 61 (65) MSEK, a decrease of -6%.
• Net sales amounted to 58 (64) MSEK, a decrease of -10%, whereof -8% organic, 2% acquired and -4% currency effect.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to -6.2 (4.0) MSEK.
• Net income for the period amounted to -13.1 (0.0) MSEK.
• Earnings per share (EPS) were -0.51 (0.00) SEK.
• Cash flow from operating activities amounted to -2.7 (42.3) MSEK.

NINE MONTHS 2024 (JUL - SEP)

• Order intake amounted to 170 (200) MSEK, a decrease of -15%.
• The order book by the end of the period was 117 (129) MSEK, a decrease of -9%.
• Net sales amounted to 204 (203) MSEK, an increase of 0%, whereof -1% organic, 1% acquired and 0% currency effect.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to -0.1 (21.9) MSEK.
• Net income for the period amounted to -20.5 (0.0) MSEK.
• Earnings per share (EPS) were -0.80 (0.00) SEK.
• Cash flow from operating activities amounted to 4.5 (44.8) MSEK.

Webcast presentation of the interim report
Date: November 7, 2024
Time: 10:00 CET

To join the presentation, please visit https://investor.mentice.com/